Code Moment | Qiheshengke Biotechnology Closes Over 100 Million RMB Series A+ Round, Embarking on a New Chapter in Gene Editing Commercialization

Today, MaHui portfolio company Qiheshengke Biotechnology announced the completion of an A+ round exceeding RMB 100 million. This round was led by CITIC Agriculture Industry Fund, with joint participation from Bailian Capital, Xinjian Future Fund, Nanjing Innovation Investment Group, and Xingbo Fund. WinX Capital served as the exclusive financial advisor. The proceeds will be used primarily for core gene-editing technology iteration, pipeline advancement, commercialization, and global market expansion.

Source Code Capital participated in the company's Pre-A round in 2023 and has continued to support the company since.

Since its founding, Qiheshengke Biotechnology has attracted significant capital market attention for its leading technological innovation capabilities, with cumulative fundraising reaching several hundred million RMB through this round. The A+ round brings together leading agricultural technology industrial capital, synthetic biology manufacturing specialist funds, consumer technology empowerment capital, and local state-backed innovation investment platforms — an investor lineup that combines industrial resources, technological synergies, and regional empowerment advantages, further confirming the capital market's firm confidence in Qiheshengke's technical approach, R&D strength, and commercialization prospects.

Yang Haiquan, co-founder and COO of Qiheshengke Biotechnology, said: "The company has entered a critical period of industrial deployment. The successful completion of this financing will accelerate product rollout and global commercialization. Gene-editing technology has already demonstrated tremendous competitiveness in global bio-agriculture and bio-manufacturing industries. Qiheshengke will continue to accelerate product and service innovation, create customer value, and lead industry development."

Dr. Zhao Tianmeng, co-founder, CEO and CTO of Qiheshengke Biotechnology, said: "The successful completion of the A+ round is an important milestone for the company. We will continue to invest in the R&D and iteration of core gene-editing tools, expand our multi-product pipeline, and deepen cooperation with domestic and international institutions and customers to drive proprietary gene-editing technology toward large-scale application and global deployment."

Going forward, Qiheshengke Biotechnology will continue to focus on gene-editing technology innovation, insist on independent R&D and industrial collaboration, and build a complete closed loop from technology breakthroughs to market application — empowering the bio-agriculture and bio-manufacturing industries with hardcore technology and striving to lead the development of the global future bio-industry.